- Kazia Therapeutics (KZA) sees new data presented for its brain cancer drug, Paxalisib, highlighting its use in two forms of childhood brain cancer
- The data has been presented in two poster presentations at the International Symposium on Pediatric Neuro-Oncology (ISPNO) in Germany
- The first describes the activity of Paxalisib in combination with a second drug in animal models of brain tumours
- The second poster presents work which will underpin phase two clinical trial safety and efficacy of Paxalisib in combination with ONC201 to treat a form of brain cancer
- KZA says the data from this study will underpin phase two clinical trial safety and efficacy of combining Paxalisib and ONC201 for treatment of brain cancer
- Shares in the company last traded at 78 cents each on June 10
Kazia Therapeutics (KZA) have new data presented for its brain cancer drug, Paxalisib, highlighting its use in two forms of childhood brain cancer.
The data was presented in two poster presentations at the International Symposium on
Pediatric Neuro-Oncology (ISPNO) in Germany.
The first described the activity of Paxalisib in combination with a second drug in animal models of brain tumours. This data helped build on work previously presented at the American Association of Cancer Research (AACR) Annual Meeting in April 2022.
The second poster presented work conducted by the Hunter Medical Research Institute, which involved collaboration with ten international laboratories and paediatric centres.
The research involved Paxalisib’s use in combination with ONC201 to treat a form of brain cancer in animal models and two clinical case studies.
The company said the data from this study will underpin phase two clinical trial safety and efficacy of combining Paxalisib and ONC201 for treatment of brain cancer.
“We are excited to see such an emphatic demonstration of the potential for ONC201 and Paxalisib to provide benefit in this disease,” CEO Dr James Garner said.
It has scheduled investor webinar to discuss the new ISPNO data, which will outline the success of the research and its plan going forward.
Shares in the company last traded at 78 cents each on June 10.